Bitwise predicts Bitcoin could surpass $100,000 by the end of 2026 due to institutional demand and ETF inflows, while LO forecasts a more cautious range of $85,000 to $95,000, citing inflation and potential Federal Reserve rate hikes as risks. Bitcoin's price rebound above $90,000 could trigger further gains toward $100,000 if supported by sustained institutional buying and easing inflation. Investors will closely watch US inflation data, energy prices, and Fed policy decisions to gauge Bitcoin's trajectory.
Bitcoin price forecasts for 2026 provide context for cryptocurrency market activity on Pluang. For readers following crypto assets, here is Pluang's market snapshot as of Oct 20, 2026 00:31 WIB: out of 50 major cryptocurrencies, 40 rose and 9 fell today. BAT gained 5.08% to Rp3.243 with a near-even Pluang order split of 49% Sell / 51% Buy and a typical hold time of 93 days, while UNI rose 4.40% to Rp131.503 with 66% Buy orders and a shorter hold time of 65 days. EGLD increased 4.24% to Rp64.954, with 57% Buy orders and a typical hold time of 86 days.
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted thera...
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
